Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1987 2
1988 5
1989 5
1990 1
1991 2
1992 2
1993 1
1995 3
1998 1
2006 1
2012 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells.
Kondo S, Tanaka N, Kubota S, Mukudai Y, Yosimichi G, Sugahara T, Takigawa M. Kondo S, et al. Mol Cancer Ther. 2006 Jan;5(1):129-37. doi: 10.1158/1535-7163.MCT-05-0097. Mol Cancer Ther. 2006. PMID: 16432171
By employing a RNA degradation assay, we eventually found that the observed increase in the ctgf/ccn2 mRNA level was due to an increased stability of the mRNA induced by VEGF. DN-9693 at a dose of 0.1 to 2 ng/mL did not affect basal levels of ctgf/ccn2 mRNA; however …
By employing a RNA degradation assay, we eventually found that the observed increase in the ctgf/ccn2 mRNA level was due to an increased sta …
Effects of DN-9693, a synthesized phosphodiesterase inhibitor, on pancreatic exocrine secretion in dogs.
Iwatsuki K, Horiuchi A, Yonekura H, Haruta K, Homma N, Chiba S. Iwatsuki K, et al. Jpn J Pharmacol. 1989 Jan;49(1):77-82. doi: 10.1254/jjp.49.77. Jpn J Pharmacol. 1989. PMID: 2470943 Free article.
DN-9693 injected intraarterially caused a dose-dependent increase in the secretion of pancreatic juice and decrease in the perfusion pressure. ...The concentration of bicarbonate in the pancreatic juice induced by DN-9693 was increased, but protein con …
DN-9693 injected intraarterially caused a dose-dependent increase in the secretion of pancreatic juice and decrease in the per …
Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Tanaka NG, Tohgo A, Ogawa H, Osada Y. Tanaka NG, et al. Anticancer Res. 1986 Jul-Aug;6(4):543-8. Anticancer Res. 1986. PMID: 3019218
1,5-Dihydro-7-(1-piperidinyl)-imidazo[2,1-b]quinazolin-2(3H)-one dihydrochloride hydrate (DN-9693), a new c-AMP: phosphodiesterase inhibitor was examined for its inhibi …
1,5-Dihydro-7-(1-piperidinyl)-imidazo[2,1-b]quinazolin-2 …
Determination of 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (DN-9693) in human plasma and urine by high-performance liquid chromatography with electrochemical detection: application to studies on disposition of DN-9693 in healthy human volunteers.
Tanaka M, Yamada M, Ono K, Takegoshi T. Tanaka M, et al. J Pharm Sci. 1987 Mar;76(3):235-7. doi: 10.1002/jps.2600760311. J Pharm Sci. 1987. PMID: 3035171
A procedure for the determination of a newly developed antiadhesive agent, 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-on e (DN-9693; 1), in human plasma and urine at low nanogram levels by high-performance liquid chromatography with electrochemical de …
A procedure for the determination of a newly developed antiadhesive agent, 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-on e ( …
Comparison of vasodilator effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, and isobutylmethylxanthine, a non-selective one, in dogs.
Hashimoto H, Ishii K, Satoh K, Taira N. Hashimoto H, et al. Jpn J Pharmacol. 1987 Aug;44(4):405-12. doi: 10.1254/jjp.44.405. Jpn J Pharmacol. 1987. PMID: 2446035 Free article.
The present experiments were performed in anesthetized dogs in order to determine if DN-9693, a new antiplatelet agent known to selectively inhibit cyclic AMP phosphodiesterase (PDE), and isobutylmethylxanthine (IBMX), which inhibits both cyclic AMP and GMP PDEs, ha …
The present experiments were performed in anesthetized dogs in order to determine if DN-9693, a new antiplatelet agent known t …
DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C, Ball J, Peel J, Lawry J, Greaves M, Preston FE. Jackson C, et al. Thromb Haemost. 1989 Apr 25;61(2):266-9. Thromb Haemost. 1989. PMID: 2546286
We have examined the in vitro effects of DN 9693 (piperidinylimidazo-quinazolinone) on various aspects of platelet reactivity. ...Our results indicate that in addition to its anticipated inhibitory effect on platelet aggregation, DN 9693 may also inhib …
We have examined the in vitro effects of DN 9693 (piperidinylimidazo-quinazolinone) on various aspects of platelet reactivity. …
Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
Akahane K, Furukawa Y, Haniuda M, Karasawa Y, Chiba S. Akahane K, et al. Jpn Heart J. 1989 Nov;30(6):903-15. doi: 10.1536/ihj.30.903. Jpn Heart J. 1989. PMID: 2561162
The positive chronotropic effect of DN-9693 was about 10 times more potent, but the maximal increase in heart rate was much less than that produced by sulmazole. ...DN-9693 possesses more potent cardiotonic and vasodilating effects than sulmazole, and …
The positive chronotropic effect of DN-9693 was about 10 times more potent, but the maximal increase in heart rate was much le …
Effects of a new inotropic drug (DN-9693) on Ca2+ transients and contraction in ferret ventricular muscles.
Tanaka T, Kawai M, Kurihara S. Tanaka T, et al. J Cardiovasc Pharmacol. 1995 Aug;26(2):227-32. doi: 10.1097/00005344-199508000-00008. J Cardiovasc Pharmacol. 1995. PMID: 7475047
The potentiation of Ca2+ transients by DN-9693 was significant at lower concentrations (1-10 microM) but not at higher concentrations (50 and 100 microM). ...Other parameters of Ca2+ transients were not significantly altered. The time course of tension was not affec …
The potentiation of Ca2+ transients by DN-9693 was significant at lower concentrations (1-10 microM) but not at higher concent …
Effect of a cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury.
Chang-Chun C, Matsuda H, Sawa Y, Kaneko M, Sakagoshi N, Nishimura M, Kuratani T, Amemiya A, Kawashima Y. Chang-Chun C, et al. Ann Thorac Surg. 1991 Sep;52(3):495-9. doi: 10.1016/0003-4975(91)90911-9. Ann Thorac Surg. 1991. PMID: 1654868
A new cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, was examined to see whether myocardial reperfusion injury could be reduced in a setting of cardioplegic arrest through its antiaggregation effect on leukocytes. ...A dose of 20 micrograms.kg- …
A new cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, was examined to see whether myocardial reperfusion …
27 results